Is Marijuana a Rite of Passage?

Listen to Dr. Robert DuPont’s discussion on High Truths on Drugs and Addiction, Episode # 13.

Is marijuana a rite of passage? Is drug use, like sex, inevitable in teens and young adults? Listen to Dr. Robert DuPont’s discussion on High Truths on Drugs and Addiction, Episode # 13. Dr. Dupont is an IASIC physician advisor, the first director of the National Institute on Drug Abuse (NIDA) and our nation’s second Drug Czar.

Dr. DuPont gets right to the data in challenging the myth that “everyone uses marijuana.” That’s not what the data states. Most teens do not use weed. Using drugs is not a biological need such as sex or reproduction. The animal kingdom is not naturally attracted to drugs that are destructive to their species. Dr. Dupont promotes the Once Choice program – no alcohol, nicotine or marijuana until age 25 when the brain is done growing. That is the best way to prevent and greatly decrease drug overdose in our country.

Listen Now

About Robert L. DuPont, MD
For 50 years, Robert L. DuPont, MD has been a leader in drug abuse prevention and treatment. He was the first Director of the U.S. National Institute on Drug Abuse (1973-1978) and the second White House Drug Chief (1973-1977). From 1968-1970 he was Director of Community Services for the District of Columbia Department of Corrections. From 1970-1973, he served as Administrator of the District of Columbia Narcotics Treatment Administration. In 1978 he became the founding President of the Institute for Behavior and Health, Inc., a non-profit research and policy organization that identifies and promotes powerful new ideas to reduce drug use and addiction. A graduate of Emory University, Dr. DuPont received an MD degree in 1963 from the Harvard Medical School. He completed his psychiatric training at Harvard and the National Institutes of Health in Bethesda, Maryland. Dr. DuPont maintains an active practice of psychiatry specializing in addiction and the anxiety disorders and has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980.

He is the author of Chemical Slavery: Understanding Addiction and Stopping the Drug Epidemic published in 2018.

For more about Dr. DuPont’s work and the Institute for Behavior and Health, Inc. visit www.IBHinc.orgwww.StopDruggedDriving.org, and www.OneChoicePrevention.org.

Listen to Episode #13 Now

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here. The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

Weed users nearly 25% more likely to need emergency care and hospitalization

The study, published Monday in the journal BMJ Open Respiratory Research, looked at national health records data for over 30,000 Ontario, Canada, residents between the ages of 12 and 65 over a six-year period. When compared with people who did not use marijuana, cannabis users were 22% more likely to visit an emergency department or be

Cannabis use is associated with increased risk for serious adverse health events

Although no significant association was observed between cannabis use and respiratory-related ER visits or hospitalisations, the risk of an equally important morbidity outcome, all-cause ER visit or hospitalisation, was significantly greater among cannabis users than among control individuals. Therefore, cannabis use is associated with increased risk for serious adverse health events and its recreational consumption

Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores

Products containing cannabinoids such as cannabidiol (CBD) have proliferated since 2018, when the Agriculture Improvement Act removed hemp (ie, cannabis containing <0.3% Δ9-tetrahydrocannabinol [THC]) from the US controlled substances list. Topical cannabinoid products can be purchased nationwide at retail stores and over the internet, yet research on these products is scarce. The objective of this

Cannabis-Derived Oromucosal Spray Misses in MS Spasticity Trial

Topline results were announced from a phase 3 trial evaluating the efficacy and safety of nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in adults with multiple sclerosis. Nabiximols oromucosal spray is an investigational complex botanical mixture formulated from extracts of the cannabis sativa plant. The investigational treatment contains the cannabinoids delta-9-tetrahydrocannabinol (THC) and

Should the UK legalize marijuana?

After Sadiq Khan’s visit to a California cannabis farm, discussions of legalising the herb here in the UK has been brought back into the spot light. But is Mr. Khan’s glowing review of the US marijuana industry all it’s cracked up to be? The Medical Minefield speak with Michelle Leopold, whose campaigning for safer drug

Scroll to Top